Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Equity Average (2020 - 2025)

Maxcyte (MXCT) has disclosed Equity Average for 6 consecutive years, with $185.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 14.63% to $185.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $185.5 million, a 14.63% decrease, with the full-year FY2024 number at $219.2 million, down 9.82% from a year prior.
  • Equity Average was $185.5 million for Q3 2025 at Maxcyte, down from $195.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $263.5 million in Q4 2021 to a low of $57.3 million in Q1 2021.
  • A 5-year average of $212.3 million and a median of $229.3 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 672.52% in 2021, then fell 14.63% in 2025.
  • Maxcyte's Equity Average stood at $263.5 million in 2021, then decreased by 3.53% to $254.2 million in 2022, then dropped by 8.43% to $232.8 million in 2023, then decreased by 9.88% to $209.8 million in 2024, then fell by 11.57% to $185.5 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Equity Average are $185.5 million (Q3 2025), $195.1 million (Q2 2025), and $202.8 million (Q1 2025).